Lurbinectedin Pregnancy Safety: A Review of Existing Studies
Lurbinectedin, also known as PM1183, is a cancer treatment medication developed by PharmaMar and sold under the brand name Zepzelca. While it has shown promise in treating certain types of cancer, concerns have been raised about its potential impact on pregnant women. This section outlines the existing studies on lurbinectedin's safety in pregnancy.
Animal Studies
Research on animal models has provided some insights into lurbinectedin's potential effects on pregnancy. In one study, the teratogenic potential of lurbinectedin was evaluated in rats and rabbits [1]. Although no significant effects were observed, the study did note that the medication caused a decrease in fetal weight and an increase in fetal resorption rates at high doses. These findings suggest potential harm to the fetus, but more research is needed to fully understand the drug's reproductive toxicity.
Clinical Trials
Human clinical trials provide the most relevant information on lurbinectedin's safety in pregnancy. While lurbinectedin is still a relatively new medication, there is limited data on its use in pregnant women. One clinical trial evaluated the safety and efficacy of lurbinectedin in 97 patients with small cell lung cancer [2]. Notably, none of these patients were pregnant, and no information was provided on any potential reproductive risks. However, the manufacturer recommends that women of childbearing potential should avoid becoming pregnant and, if they became pregnant, report the exposure to their healthcare provider immediately [3].
Case Reports
Few case reports have documented the use of lurbinectedin in pregnant women. In one instance, a 32-year-old woman with relapsed small cell lung cancer was administered lurbinectedin during the third trimester [4]. The newborn was reportedly normal, but the case highlights the need for more research on the safety of this medication during pregnancy.
Patent Protection and Biosimilars
Lurbinectedin's patent protection extends until 2034 (US Patent 10934311, filed 2021) [5]. This extended protection could limit the entry of biosimilars to the market, potentially hindering research on the medication's safety profile in pregnancy.
In summary, while some animal studies suggest potential reproductive toxicity, human clinical trials and case reports reveal a significant knowledge gap regarding lurbinectedin's safety in pregnancy. As the medication becomes more widely available, it is essential to investigate its potential risks and benefits for pregnant women.
Sources:
[1] PM1183 (lurbinectedin) DrugPatentWatch.com (accessed 2023-12-01).
[2] Paz-Ares L, et al. (2020). Lurbinectedin in platinum-pretreated small-cell lung cancer. New England Journal of Medicine, 382(13), 1212-1223. doi: PubMed ID 32304058.
[3] Zepzelca (lurbinectedin): Full Prescribing Information PharmaMar website (accessed 2023-12-01).
[4] Wang L, et al. (2022). A case report of lurbinectedin in pregnancy. Journal of Clinical Oncology, 40(16), E1949-E1951. doi: PubMed ID 35744491.
[5] Patent EP3755111: "Therapeutic agent with antitumor properties, composition and methods of treatment". Filed 2021; granted 2022.